Anthim
obiltoxaximab · B. anthracis PASingle-dose clinical escalation supported by monkey AUC margin: 10 mg/kg AUC ~50,000 µg·hr/mL vs human AUC 10,000 at 114 mg
The public FDA and EMA reviews of Jemperli don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.
ADCs with cytotoxic payloads follow the S9 rules (1/10 STD10 or 1/6 HNSTD of the ADC, scaled by body surface area). For immune agonists, a MABEL-based start dose should be considered instead.
NOAEL / key findings: NOAEL not established in 13-week monkey study due to an immune-type skin finding in one low-dose (10 mg/kg) animal (EMA assessment report, p. 43)